Pharma Focus Asia

Ubiquigent Extends And Expands Drug Discovery Collaboration With Bristol Myers Squibb

Friday, October 29, 2021

Ubiquigent Limited announces the extension and expansion of its long-term collaboration with Bristol Myers Squibb. Under the terms of the agreement, Ubiquigent will provide Bristol Myers Squibb with increased access to its deubiquitylase (DUB) enzyme inhibitor drug discovery platform to provide further support to additional therapeutic areas.

The central role of ubiquitylation in diverse cellular processes, including but not limited to protein degradation, makes the enzymes responsible for ubiquitylation and de-ubiquitylation highly attractive drug targets with the potential to address a wide range of human pathologies.

Recently, there has been further growing interest in the development of modulators of various components of the ubiquitin-proteasome system (UPS) for therapeutic benefit. Strategies that are being actively pursued include the exploitation of the UPS via PROTACs and molecular glues to target the undruggable proteome and the development of DUB inhibitors.

Ubiquigent has established itself as a respected global partner in the UPS field with a particular focus on the development of DUB inhibitors, with an established track record of supporting the drug discovery efforts of its partners via access to its Drug Discovery Screening Platform and by providing access to its own developing portfolio of novel DUB inhibitors as part of larger partnerships.

Ubiquigent’s CEO, Jason Mundin commented: “We are delighted to have the opportunity to build on our existing relationship with Bristol Myers Squibb in this rapidly evolving field to provide additional support to the development of novel DUB inhibitors for patients with unmet medical needs.”

magazine-slider-image
magazine-slider-image
Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024